LSP 7 Cooperative UA bought $25M of EVMN
owner at Evommune, Inc.. 1,562,500 shares at an average of $16.00, traded Nov 7, 2025, filed Nov 12, 2025.
Score components
- +12Role10% owner
- +25Trade size$25.0M at market
- +6Relative to holdingsHoldings up 46%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.7%, 3m +45.8%, 6m +19.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001876264-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | CConversion Common Stock | +3,367,133 | - | - | 3,367,133 | Nov 12, 2025 |
| Nov 7, 2025 | POpen-market purchase Common Stock | +1,562,500 | $16.00 | $25M | 4,929,633 | Nov 12, 2025 |
| Nov 7, 2025 | CConversion Series A Preferred Stockderivative | -15,493,466 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | CConversion Series B Preferred Stockderivative | -5,090,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | CConversion Series C Preferred Stockderivative | -6,585,011 | - | - | 0 | Nov 12, 2025 |
Related signals
Other insiders at Evommune, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | Evommune, Inc. | Kyle Carver Chief Financial Officer | $13k 1,000 shares | +2% | |
| 60Notable | Evommune, Inc. | Arthur S Kirsch director | $133k 10,000 shares | - | |
| 17Weak | Evommune, Inc. | Janice Suzann Drew Chief of Dev. Operations | $453k 20,000 shares | -23% | |
| 31Weak | Evommune, Inc. | Luis C. Pena President & CEO | $169k 7,438 shares | -1% | |
| 1Weak | Evommune, Inc. | Jeegar Pravinkumar Patel Chief Scientific Officer | $33k 1,488 shares | -3% | |
| 30Weak | Evommune, Inc. | David E Cohen director | $123k 6,056 shares | -26% | |
| 36Weak | Evommune, Inc. | Luis C. Pena President & CEO | $382k 16,787 shares | -3% | |
| 21Weak | Evommune, Inc. | Jeegar Pravinkumar Patel Chief Scientific Officer | $379k 16,687 shares | -26% | |
| 23Weak | Evommune, Inc. | Kyle Carver Chief Financial Officer | $415k 18,175 shares | -23% | |
| 14Weak | Evommune, Inc. | Gregory S. Moss Chief Business & Legal Officer | $325k 14,223 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.